IRCT20211203053261N2
Completed
Phase 3
Evaluation of the Effect of Empagliflozin drug in prevention of urinal parameters increase in urolithiasis.
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Hamedan University of Medical Sciences
- Enrollment
- 138
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients in the age range of 18 to 65 years
- •Patients with a history of kidney stones in the last 5 years
Exclusion Criteria
- •Diabetic patients
- •Taking antidiabetic drugs
- •Taking diuretic drugs
- •Chronic kidney disease patients
- •Patients with genital infections
- •Patients with urinary infections
- •breastfeeding
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 3
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44
Not Yet Recruiting
Phase 3
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patientsCTRI/2024/02/063292SRM Insitute of Science and Technology
Recruiting
Phase 3
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90
Recruiting
Phase 3
Evaluation of the effectiveness of Empagliflozin on metabolic factors and liver function testsIRCT20191209045671N3Semnan University of Medical Sciences60
Completed
Phase 1
Empagliflozin in non alcoholic fatty liverDiabetic patient with non alcoholic fatty liver.Other specified inflammatory liver diseasesK75.8IRCT20150706023084N18Islamic Azad University30